USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$710.17M
Market Cap
-
P/E Ratio
-2.5
EPS
$10.38
52 Week High
$1.45
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$2M |
| Total Revenue | $0 |
| Cost Of Revenue | $2M |
| Costof Goods And Services Sold | $2M |
| Operating Income | -$106M |
| Selling General And Administrative | $32M |
| Research And Development | $74M |
| Operating Expenses | $106M |
| Investment Income Net | - |
| Net Interest Income | $7.4M |
| Interest Income | $7.6M |
| Interest Expense | $114K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2M |
| Income Before Tax | -$98M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$98M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$98M |
| Ebitda | -$96M |
| Net Income | -$98M |
| Field | Value (USD) |
|---|---|
| Total Assets | $147M |
| Total Current Assets | $126M |
| Cash And Cash Equivalents At Carrying Value | $35M |
| Cash And Short Term Investments | $35M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $21M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | $7M |
| Short Term Investments | $87M |
| Other Current Assets | $4.6M |
| Other Non Current Assets | - |
| Total Liabilities | $30M |
| Total Current Liabilities | $23M |
| Current Accounts Payable | $6.4M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2.7M |
| Total Non Current Liabilities | $7.3M |
| Capital Lease Obligations | $9.9M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $9.9M |
| Other Current Liabilities | $14M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $117M |
| Treasury Stock | - |
| Retained Earnings | -$280M |
| Common Stock | $3K |
| Common Stock Shares Outstanding | $32M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$2M |
| Total Revenue | $0 |
| Cost Of Revenue | $2M |
| Costof Goods And Services Sold | $2M |
| Operating Income | -$106M |
| Selling General And Administrative | $32M |
| Research And Development | $74M |
| Operating Expenses | $106M |
| Investment Income Net | - |
| Net Interest Income | $7.4M |
| Interest Income | $7.6M |
| Interest Expense | $114K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $2M |
| Income Before Tax | -$98M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$98M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$98M |
| Ebitda | -$96M |
| Net Income | -$98M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Lexeo Therapeutics, Inc. is a New York-based clinical-stage genetic medicine company dedicated to developing pioneering therapies for hereditary and acquired diseases. Leveraging advanced gene-editing technologies, Lexeo is advancing a robust and diverse pipeline of innovative treatments aimed at addressing significant unmet medical needs and enhancing patient outcomes. With a strong commitment to proprietary platform development, Lexeo is well-positioned to make a substantial impact in the burgeoning field of genetic medicine, representing a compelling opportunity for institutional investors interested in transformative healthcare solutions.